We have evaluated the long-term (18 months) effectiveness of the addition of once-daily insulin glargine (bedtime or morning) in the treatment of 44 type 2 diabetic patients (male/female: 27/17, mean HbA1c: 9.7 ± 1.6%) who had taken the maximum or a semi-maximum dose of sulfonylurea for more than a year but had not shown reduction of the HbA1c to below 7.5%. After 6 months, we divided the patients into two groups ; improved group, in which the HbA1c decreased to below 7.0% (n = 11, mean HbAc: 6.7 ± 0.3%), and the no-improvement group, in which sustained elevation of HbA1c at over 7.0% (n = 16, mean HbA1c: 8.3 ± 1.2%) was observed. In the improved group, the mean HbA1c after 18 months was still below 7.0% (6.9 ±0.6%; p < 0.001) and the dose of insulin glargine had not increased significantly. On the other hand, in the no-improvement group, no further improvement of the HbA1c value was observed between 6 and 18 months (8.3 ±1.3%) despite the significant increase in the dose of insulin glargine (9.3±4.8U ⇒ 14.3 ± 7.1U). These results suggest that this novel combination therapy shows long-term effectiveness, and may be recommended as a treatment of first-choice for patients who have difficulty in accepting intensive insulin therapy.
|Number of pages||7|
|Journal||Journal of the Japan Diabetes Society|
|Publication status||Published - 2007 Oct 22|
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism